9-months | 12-months | 15-months | |||||||
---|---|---|---|---|---|---|---|---|---|
Discontinuous users (n = 292) | Continuous users (n = 452) | p* | Discontinuous users (n = 382) | Continuous users (n = 317) | p* | Discontinuous users (n = 489) | Continuous users (n = 164) | p* | |
STEMI | 60 (20.6%) | 124 (27.4%) | 0.03* | 95 (24.9%) | 80 (25.2%) | 0.91 | 127 (26.0%) | 35 (21.3%) | 0.23 |
NSTEMI | 22 (7.5%) | 76 (16.8%) | <0.001* | 41 (10.7%) | 52 (16.4%) | 0.03* | 62 (12.7%) | 26 (15.9%) | 0.30 |
Non-elective PCI | 43 (14.7%) | 91 (20.1%) | 0.06 | 69 (18.1%) | 57 (18.0%) | 0.98 | 89 (18.2%) | 27 (16.5%) | 0.61 |
IABP use | 3 (1.0%) | 8 (1.8%) | 0.54 | 4 (1.1%) | 7 (2.2%) | 0.22 | 7 (1.4%) | 3 (1.8%) | 0.72 |
GP IIb IIIa inhibitors | 7 (2.4%) | 15 (3.3%) | 0.47 | 12 (3.1%) | 10 (3.2%) | 0.99 | 15 (3.1%) | 7 (4.3%) | 0.19 |
Number of diseased vessels | 1.90 ± 0.85 | 2.03 ± 0.85 | 0.04* | 1.91 ± 0.86 | 2.06 ± 0.85 | 0.02* | 1.93 ± 0.86 | 2.04 ± 0.84 | 0.19 |
Multivessel PCI | 93 (31.9%) | 157 (34.7%) | 0.42 | 115 (30.1%) | 119 (37.5%) | 0.04* | 151 (30.9%) | 68 (41.5%) | 0.01* |
Total occlusion | 76 (26.0%) | 153 (33.9%) | 0.02* | 106 (27.8%) | 108 (34.1%) | 0.07 | 142 (29.0%) | 56 (34.2%) | 0.22 |
Ostium lesion | 18 (6.2%) | 42 (9.3%) | 0.13 | 24 (6.3%) | 28 (8.8%) | 0.20 | 29 (5.9%) | 19 (11.6%) | 0.01* |
Bifurcation lesion | 11 (3.8%) | 25 (5.5%) | 0.27 | 12 (3.1%) | 18 (5.7%) | 0.10 | 17 (3.5%) | 10 (6.1%) | 0.14 |
Location of stent | |||||||||
RCA | 92 (31.5%) | 162 (35.8%) | 0.22 | 118 (30.9%) | 124 (39.1%) | 0.02* | 161 (32.9%) | 61 (37.2%) | 0.32 |
LAD | 177 (60.6%) | 281 (62.2%) | 0.67 | 238 (62.3%) | 195 (61.5%) | 0.83 | 303 (62.0%) | 104 (63.4%) | 0.74 |
LCX | 78 (26.7%) | 128 (28.3%) | 0.63 | 99 (25.9%) | 91 (28.7%) | 0.41 | 131 (26.8%) | 52 (31.7%) | 0.22 |
LM | 12 (4.1%) | 27 (6.0%) | 0.27 | 13 (3.4%) | 19 (6.0%) | 0.10 | 18 (3.7%) | 12 (7.3%) | 0.05* |
Number of stents | |||||||||
1 stent | 159 (54.5%) | 219 (48.5%) | 0.11 | 206 (53.9%) | 147 (46.4%) | 0.08 | 261 (53.4%) | 67 (40.9%) | 0.02* |
≥ 2 stents | 122 (41.8%) | 222 (49.1%) | 163 (42.7%) | 162 (51.1%) | 215 (44.0%) | 91 (55.5%) | |||
At least 1 DES | 185 (63.4%) | 369 (81.6%) | <0.001* | 252 (66.0%) | 271 (85.5%) | <0.001* | 350 (71.6%) | 140 (85.4%) | <0.001* |
Paclitaxel | 53 (18.2) | 103 (22.8) | 0.13 | 72 (18.9) | 75 (23.7) | 0.12 | 91 (18.6) | 44 (26.8) | 0.02* |
Sirolimus | 76 (26.0) | 134 (29.7) | 0.28 | 103 (27.0) | 94 (29.7) | 0.43 | 139 (28.4) | 49 (29.9) | 0.72 |
Zotarolimus | 49 (16.8) | 105 (23.2) | 0.03* | 65 (17.0) | 84 (26.5) | 0.002* | 95 (19.4) | 43 (26.2) | 0.07 |
Everolimus | 12 (4.1) | 45 (10.0) | 0.003* | 19 (5.0) | 35 (11.0) | 0.003* | 35 (7.2) | 14 (8.5) | 0.56 |
EPC-capturing | 11 (3.8) | 13 (2.9) | 0.50 | 15 (3.9) | 7 (2.2) | 0.20 | 17 (3.5) | 4 (2.4) | 0.62 |
Total stent length (mm) | 39.6 ± 25.1 | 45.5 ± 30.2 | 0.01* | 39.7 ± 24.9 | 46.9 ± 31.1 | 0.001* | 41.4 ± 26.8 | 49.0 ± 32.7 | 0.01* |
Min. stent diameter (mm) | 3.04 ± 0.43 | 2.96 ± 0.47 | 0.03* | 3.03 ± 0.44 | 2.95 ± 0.46 | 0.03* | 3.0 ± 0.4 | 3.0 ± 0.5 | 0.27 |